Dual Roles of Lactate in EGFR-TKI-Resistant Lung Cancer by Targeting GPR81 and MCT1

Figure 1

Lactate reduces cytotoxicity induced by erlotinib in lung cancer cells. (a) PC9 and HCC827 cells were pretreated with different concentration of erlotinib, and 2 μM erlotinib could reduce about 50% cell viability of both PC9 and HCC827 cells (upper). CCK-8 assay was performed in the condition of different concentration of lactate (1, 5, 10, and 20 mM) before erlotinib (2 μM). 10 mM lactate could significantly promote the cell viability in both PC9 and HCC827 cells treated with erlotinib (lower). (b) HCC827 and PC9 cells were cultured with 10 mM lactate (right) or untreated (left), and then treated with 2 μM erlotinib. The percentage of apoptosis was measured with flow cytometry. All values are mean ± S.D (n ≥ 3). .

(a)

(b)